ReviewInternational journal of molecular sciences2022
Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07499635 (Immunophenotypic Evaluation of Inhibitory Immune Receptors CD305 and CD85d in B-Cell Lymphoid Neoplasms), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunophenotypic Evaluation of Inhibitory Immune Receptors CD305 and CD85d in B-Cell Lymphoid Neoplasms
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis of the prognostic significance of CDKN deletions in acute lymphoblastic leukaemia.Annals of medicine · 2024Pooled it
- Clinical Outcome and Prognostic Factors in Childhood Acute Lymphoblastic Leukemia-A Retrospective Cohort Study of Patients from Southern Mexico.Journal of clinical medicine · 2026Article
- Article
- [Effect of inorganic pyrophosphatase PPA1 on proliferation and apoptosis of abnormal naive cells in acute B-lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Favorable outcome in TCF3::HLF-positive pediatric B-cell acute lymphoblastic leukemia without classic metabolic complications: A case report.Annals of hematology · 2026Article
- Semaphorin 4D (CD100) expression as a predictor for the response to induction therapy in pediatric patients with B-acute lymphoblastic leukemia.European journal of pediatrics · 2026Article
- Article
- Single Nucleotide Polymorphism Microarray Analysis Unveils Copy-Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.Molecular genetics & genomic medicine · 2026Article
- Interplay between monocyte subsets and leukemic blasts shapes the immune microenvironment and sustains minimal residual disease in pediatric B-cell acute lymphoblastic leukemia.Frontiers in immunology · 2026Article
- Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge.Frontiers in pediatrics · 2026Article
- Serum miR-493-3p as a diagnostic biomarker and epigenetic regulator targeting DPY30 in pediatric acute lymphoblastic leukemia.Annals of hematology · 2025Article
- Low expression of MKRN1 promotes leukemia cell proliferation.European journal of medical research · 2025Article
- Polyamines at the crossroad between cell metabolism and epigenetic regulation in acute leukemias.Cell death discovery · 2025Review
- [Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemia.Molecular biology reports · 2025Review
- Dysregulation of the Bone Marrow Microenvironment in Pediatric Tumors: The Role of Extracellular Vesicles in Acute Leukemias and Neuroblastoma.International journal of molecular sciences · 2025Review
- Article
- RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia.British journal of haematology · 2025Article
- Article
- Genomic landscape of childhood acute lymphoblastic leukemia in Malaysia: insights from array-CGH.Molecular cytogenetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies characterized by abnormal proliferation of immature lymphoid cells. It is the most commonly diagnosed childhood cancer with an almost 80% cure rate. Despite favorable survival rates in the pediatric population, a significant number of patients develop resistance to therapy, resulting in poor prognosis. ALL is a heterogeneous disease at the genetic level, but the intensive development of sequencing in the last decade has made it possible to broaden the study of genomic changes. New technologies allow us to detect molecular changes such as point mutations or to characterize epigenetic or proteomic profiles. This process made it possible to identify new subtypes of this disease characterized by constellations of genetic alterations, including chromosome changes, sequence mutations, and DNA copy number alterations. These genetic abnormalities are used as diagnostic, prognostic and predictive biomarkers that play an important role in earlier disease detection, more accurate risk stratification, and treatment. Identification of new ALL biomarkers, and thus a greater understanding of their molecular basis, will lead to better monitoring of the course of the disease. In this article, we provide an overview of the latest information on genomic alterations found in childhood ALL and discuss their impact on patients' clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.